Biotech companies directory 2026

    Biotech Companies in Saudi Arabia

    Saudi Arabia’s biotechnology sector is being assembled to a published plan: the National Biotechnology Strategy launched in January 2024 names four plays — vaccines, biomanufacturing and localisation, genomics and plant optimisation — and backs them with Public Investment Fund capital, new SFDA guidance and hospital-based advanced-therapy manufacturing.

    The commercial centre of gravity is Lifera, the PIF biopharma company forming joint ventures with Novo Nordisk, Sanofi, Pfizer, Centogene and Jamjoom Pharma to make insulin, GLP-1 therapies, vaccines and biosimilars inside the Kingdom. Around it sit privately owned biomanufacturers such as SaudiVax, Sudair Pharma and Arabio, a hospital system led by King Faisal Specialist Hospital that now produces CAR-T cells in Riyadh, and university engines at KAUST and KACST that spin out genomics and synthetic-biology ventures. The SFDA followed with a dedicated biosimilar guideline in June 2026, while NUPCO tenders decide how fast locally filled biologics displace imports. BioNixus groups the organisations below by role so a partnering, licensing or market-access team can see who funds, who manufactures, who regulates and who buys.

    Updated September 2026 · Saudi Food and Drug Authority (SFDA) — registered biological products and licensed drug establishments as of September 2026 · 18 named accounts

    Request a proposal for Saudi ArabiaBrowse the 18 companies

    $34.6bn

    Non-oil GDP contribution targeted by the National Biotechnology Strategy for 2040

    11,000

    Biotech jobs targeted by 2030, rising to 55,000 by 2040

    15m+

    Insulin pens per year planned at Sudair Pharma’s Sudair City plant

    2,400

    Cell and gene therapy doses per year planned at KFSHRC’s Riyadh facility by 2030

    Named accounts

    Top biotechnology companies in Saudi Arabia

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Saudi Food and Drug Authority (SFDA) — registered biological products and licensed drug establishments (as of 2026-09-03).
    #CompanyHQ
    01Lifera (Pharmaceutical Investment Company)Riyadh
    02SaudiVax (SVAX)Jeddah
    03Sudair PharmaRiyadh
    04Jamjoom PharmaJeddah
    05ArabioJeddah
    06Saudi Biotechnology Manufacturing Company (SBM)Riyadh
    07King Faisal Specialist Hospital & Research Centre (KFSHRC)Riyadh
    08KAUST Innovation and Research & Technology ParkThuwal
    09King Abdulaziz City for Science and Technology (KACST)Riyadh
    10Research, Development and Innovation Authority (RDIA)Riyadh
    11Novo Nordisk Saudi ArabiaRiyadh
    12Sanofi Saudi ArabiaRiyadh
    13Pfizer Saudi ArabiaRiyadh
    14Centogene (Lifera Omics)Riyadh
    15Hikma PharmaceuticalsAmman
    16BioventureDubai
    17Saudi Food and Drug Authority (SFDA)Riyadh
    18NUPCO (National Unified Procurement Company)Riyadh

    Primary research

    These are the biotech and innovation accounts we track in Saudi Arabia

    Partnering, licensing or launching a biologic in Saudi Arabia? BioNixus runs KOL, payer and regulator interviews plus hospital-level demand sizing. Proposal within 48 hours.

    Planning research in Saudi Arabia?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in Saudi Arabia (2026)

    How the market is structured

    How biotech funding, manufacturing and partnering work in Saudi Arabia

    Capital in Saudi biotech flows from the state outward. The Public Investment Fund seeds anchor companies — Lifera and its SaudiBio and Lifera Omics subsidiaries — which then invite multinationals into localisation joint ventures where the foreign partner contributes technology transfer and the Saudi entity contributes land, offtake visibility and regulatory access. Sudair City for Industry and Business, the KAUST Research and Technology Park north of Jeddah and industrial zones around Riyadh host most of the physical capacity, with fill-finish arriving before drug-substance manufacturing. Earlier-stage ventures raise money through KAUST Innovation Ventures, the Research, Development and Innovation Authority’s grant programmes and a small group of healthcare-focused venture funds, and they tend to license in rather than discover de novo. Regulation runs through the SFDA, which registers biologics, inspects plants for GMP and, since July 2026, applies a formal biosimilar comparability pathway; pricing follows international reference baskets. Demand is concentrated: NUPCO buys for Ministry of Health clusters and many other public bodies, so a single tender award can localise a molecule’s national volume, and “Made in Saudi” preference weighting rewards domestic filling. Advanced therapies follow a different route entirely, with King Faisal Specialist Hospital manufacturing CAR-T products for its own patients under SFDA oversight and offering contract capacity to other tertiary centres. Partnering conversations therefore pass through three doors — PIF entities, SFDA and NUPCO — before they reach a private counterparty.

    Local

    PIF-backed Lifera and its subsidiaries, listed and family-owned manufacturers moving into biologics, and Jeddah and Riyadh biomanufacturers building the Kingdom’s first fill-finish and drug-substance capacity.

    • Lifera (Pharmaceutical Investment Company)
    • SaudiVax (SVAX)
    • Sudair Pharma
    • Jamjoom Pharma
    • Arabio
    • Saudi Biotechnology Manufacturing Company (SBM)

    Multinational

    Global innovators that have accepted localisation joint ventures in exchange for tender preference — insulin, GLP-1s, vaccines and diagnostics transferred into Saudi-owned plants.

    • Novo Nordisk Saudi Arabia
    • Sanofi Saudi Arabia
    • Pfizer Saudi Arabia
    • Centogene (Lifera Omics)

    Regional

    Levant and Gulf groups that manufacture injectables in Saudi Arabia or carry foreign biosimilars through SFDA registration on behalf of developers without a Saudi affiliate.

    • Hikma Pharmaceuticals
    • Bioventure

    Incubators, CDMOs & partners

    University parks, national laboratories, the research funding authority, the hospital-based cell-therapy manufacturer, and the regulator and central buyer that set the terms of entry.

    • King Faisal Specialist Hospital & Research Centre (KFSHRC)
    • KAUST Innovation and Research & Technology Park
    • King Abdulaziz City for Science and Technology (KACST)
    • Research, Development and Innovation Authority (RDIA)
    • Saudi Food and Drug Authority (SFDA)
    • NUPCO (National Unified Procurement Company)

    What is moving

    What is moving biotechnology in Saudi Arabia

    Localisation joint ventures with tender preference

    Every major localisation deal since 2024 has paired a PIF entity with a multinational, and NUPCO’s local-content weighting converts those plants into protected public volume, which pulls further insulin, vaccine and biosimilar transfers toward Sudair and Jeddah.

    Vaccine sovereignty after the pandemic

    Hajj and Umrah crowds, MERS exposure and pandemic supply shocks made end-to-end vaccine manufacturing a stated national objective, so Arabio, SaudiVax and the Lifera–Jamjoom venture are competing to become the regional antigen and filling hub.

    Hospital-made advanced therapies

    KFSHRC’s decision to manufacture CAR-T cells locally, targeting nine percent of domestic demand by 2030, creates a template for other tertiary centres and a new class of buyer for viral vectors, reagents and closed-system equipment.

    Genomics infrastructure and rare-disease burden

    High consanguinity and a young population give the Saudi Genome Program and Lifera Omics unusually rich data; newborn screening, pharmacogenomics and rare-disease diagnostics are moving from research budgets into reimbursed clinical services.

    BioNixus fieldwork

    How BioNixus studies biotechnology companies in Saudi Arabia

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Saudi Arabia:
    • Switching-intent interviews with hospital pharmacists and prescribers at MOH clusters, KFSHRC and National Guard hospitals on locally filled insulin and biosimilar monoclonal antibodies.
    • Tender landscaping of NUPCO biologics and vaccine awards over the last three cycles, including local-content scoring, bidder mix and price movements after localisation.
    • Partner due-diligence studies for multinationals comparing Lifera, Sudair Pharma, Arabio and SaudiVax on capacity, GMP status, timelines and commercial terms.
    • KOL and referral-pathway mapping across haematology-oncology centres adopting CAR-T in Riyadh, Jeddah and Dammam, covering eligibility criteria, manufacturing slot constraints, payer approvals and physician attitudes to hospital-made products.

    Biotech market research in Saudi Arabia

    Questions

    Frequently Asked Questions

    Who leads biotechnology investment in Saudi Arabia?

    The Public Investment Fund through Lifera and its subsidiaries SaudiBio and Lifera Omics. Lifera negotiates the localisation joint ventures with multinationals, is building a Jeddah CDMO and has taken a majority of the Biologics Co. venture with Jamjoom Pharma, making it the counterparty most partnering discussions eventually reach.

    Which biologics are being manufactured locally?

    Insulin filling is the most advanced, with Sudair Pharma and SaudiBio handling Sanofi and Novo Nordisk products. Vaccine fill-finish runs at Arabio with Sanofi antigens and at SaudiVax, and biosimilar monoclonal antibodies are planned by SBM and the Lifera–Jamjoom venture. Drug-substance manufacturing remains at an early stage across the board.

    How does the SFDA handle biosimilars?

    A dedicated General Guideline on Regulatory and Scientific Requirements for Development and Approval of Biosimilars took effect in July 2026, setting out comparability, reference-product and waiver expectations. It sits alongside ordinary registration, pricing, pharmacovigilance and GMP requirements, and a Saudi marketing authorisation holder is still needed.

    Where do Saudi biotech start-ups come from?

    Mostly from KAUST, whose Research and Technology Park and venture arm incubate genomics, diagnostics and synthetic-biology companies, and from KACST and university hospitals in Riyadh. Grant funding from the Research, Development and Innovation Authority and a handful of health-focused venture funds carries them to first revenue, after which many seek a licensing or manufacturing tie-up with Lifera or a listed pharmaceutical group rather than an independent scale-up.

    What research does BioNixus run on Saudi biotech organisations?

    Interviews with hospital pharmacists, oncologists and endocrinologists on willingness to switch to locally filled biologics; NUPCO tender-outcome tracking for insulin, vaccines and monoclonal antibodies; partner-evaluation studies for multinationals weighing Lifera versus private Saudi manufacturers; and clinician mapping for cell-therapy referral pathways.

    Does the order of this table reflect size or importance?

    It does not. Organisations appear because they recur in BioNixus Saudi fieldwork and in SFDA, Tadawul and PIF disclosures, and they are grouped by role — anchor investor, manufacturer, multinational partner, research institution, regulator — rather than sorted by revenue or capacity. Several early-stage KAUST ventures were left out because they have not yet reached GMP manufacturing or a registered product.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Saudi Arabia. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Saudi Food and Drug Authority (SFDA) — registered biological products and licensed drug establishments, consulted 2026-09-03. Company classification (Local / MNC / Regional / incubators, cdmos & partners) reflects ownership and role in Saudi Arabia, not size.

    • Vision 2030 — National Biotechnology Strategy targets and pillars, 2024
    • Saudi Exchange (Tadawul) disclosures by Jamjoom Pharma on the Biologics Co. subscription, 2025–2026; Lifera and SaudiVax company announcements
    • KFSHRC announcement of the gene and cell therapy manufacturing facility, October 2025; Sudair Pharma insulin plant foundation-stone coverage (SPA/Zawya), 2025
    • BioNixus Saudi Arabia biologics, vaccine and cell-therapy stakeholder fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need biotech and biologics market data in Saudi Arabia?

    Payer appetite, biosimilar uptake, KOL sentiment and tender exposure — primary research, not desk estimates.

    Planning research in Saudi Arabia?

    Primary research, market access & HEOR. Proposals within 48 hours.